SCHEMBL3092869

SCHEMBL3092869

CCOC(=O)c1cnn(Cc2ccc(Cl)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.51
GRM2 Q14416 1/20 0.51
KLKB1 P03952 2/20 0.49
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 5/20 0.47
LMNA P02545 4/20 0.47
GABRA2 P47869 1/20 0.47
GABRB2 P47870 1/20 0.47
NPSR1 Q6W5P4 2/20 0.46
HTT P42858 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
CYP19A1 P11511 1/20 0.46
POLB P06746 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
KCNH2 Q12809 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1909166 0.92 GRM2 (0.53) HSD17B10GRM2KLKB1KDM4EALDH1A1
SCHEMBL2821953 0.90 LMNA (0.54) HSD17B10GRM2KLKB1ALDH1A1SMN1; SMN2
SCHEMBL28595790 0.90 ESR1 (0.55) HSD17B10GRM2KLKB1KDM4EALDH1A1
SCHEMBL554548 0.89 GRM2 (0.51) HSD17B10GRM2KLKB1KDM4EALDH1A1
SCHEMBL553801 0.89 GRM2 (0.53) HSD17B10GRM2KLKB1KDM4EALDH1A1
SCHEMBL16246754 0.89 KLKB1 (0.57) HSD17B10GRM2KLKB1ALDH1A1LMNA
SCHEMBL3093449 0.88 GRM2 (0.63) GRM2KLKB1ALDH1A1SMN1; SMN2MAPT
SCHEMBL30739426 0.88 GRM2 (0.50) HSD17B10GRM2KLKB1KDM4EALDH1A1
SCHEMBL30739239 0.88 GRM2 (0.50) HSD17B10GRM2KLKB1KDM4EALDH1A1
SCHEMBL553854 0.88 HSD17B10 (0.60) HSD17B10GRM2KLKB1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4561993-A1 INHIBITORS OF PLASMA KALLIKREIN Rezolute, Inc. (US) 2025-06-04 EP disclosed
CN-120051460-A Plasma kallikrein inhibitors 瑞泽路特有限公司 2025-05-27 CN disclosed
WO-2024025907-A1 INHIBITORS OF PLASMA KALLIKREIN REZOLUTE, INC. (US) 2024-02-01 WO disclosed
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 HSD17B10 561/4885GRM2 840/4885KLKB1 1369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.